<div id="readability-page-1"><div> <div> , /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the &#34;Class Period&#34;), of the important May 26, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. So What: If you purchased ImmunityBio securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the ImmunityBio class action, go to https://rosenlegal.com/submit-form/?case_id=17455 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 26, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Details of the case: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) defendant Patrick Soon-Shiong materially overstated Anktiva's capabilities; and (2) as a result, defendants' statements about ImmunityBio's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the ImmunityBio class action, go to https://rosenlegal.com/submit-form/?case_id=17455 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm. Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] www.rosenlegal.com SOURCE THE ROSEN LAW FIRM, P. A. <img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTIzJk5ld3NJdGVtSWQ9REM2NjUxOSZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MjMxOTM3UFJfTkVXU19VU1BSX19fX19EQzY2NTE5?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTIzJk5ld3NJdGVtSWQ9REM2NjUxOSZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MjMxOTM3UFJfTkVXU19VU1BSX19fX19EQzY2NTE5"/></div> </div></div>

IBRX

SBIO

Rosen Law Firm is reminding investors who purchased ImmunityBio, Inc. (NASDAQ: IBRX) securities between January 19, 2026, and March 24, 2026, of the May 26, 2026, deadline to lead a securities fraud class action lawsuit. Investors may be entitled to compensation without upfront fees. The lawsuit alleges misleading statements by the company regarding its product capabilities, leading to investor losses. Interested parties can contact the firm for more information.

prnewswire

ImmunityBio

ALPS Medical Breakthrough

iShares Biotechnology ETF

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bear 3X

Proshares Ultra Nasdaq Biotech

Invesco Nasdaq Biotechnology ETF

19:37 ETIBRX Deadline: IBRX Investors with Losses in Excess of $100K Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm